
Please try another search
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Name | Age | Since | Title |
---|---|---|---|
Kelly A. Romano | 60 | 2020 | Independent Chairwoman of the Board |
Mark J. Litton | 55 | 2019 | President, CEO & Director |
Anton P. Porsteinsson | - | 2022 | Member of Scientific Advisory Board |
John Olichney | - | 2022 | Member of Scientific Advisory Board |
James A. Johnson | 67 | 2020 | Independent Director |
Barbara A. Kosacz | 66 | 2021 | Independent Director |
Pierre N. Tariot | - | 2022 | Member of Scientific Advisory Board |
Paul Winner | - | 2022 | Member of Scientific Advisory Board |
John M. Fluke | 81 | 2014 | Independent Director |
Joseph Eric Edelman | 68 | 2020 | Independent Director |
Grant E. Pickering | 56 | 2022 | Independent Director |
Michael A. Panzara | 57 | 2022 | Independent Director |
Marwan Noel Sabbagh | 58 | 2022 | Member of Scientific Advisory Board |
Hans Moebius | 67 | 2019 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review